Rathore Anurag Singh, Sobacke S E, Kocot T J, Morgan D R, Dufield R L, Mozier N M
Amgen Inc, Mail Stop 30W-2-A, One Amgen Center Drive, Thousand Oakes, CA 91320, USA.
J Pharm Biomed Anal. 2003 Aug 21;32(6):1199-211. doi: 10.1016/s0731-7085(03)00157-2.
Analyses of crude samples from biotechnology processes are often required in order to demonstrate that residual host cell impurities are reduced or eliminated during purification. In later stages of development, as the processes are further developed and finalized, there is a tremendous volume of testing required to confirm the absence of residual host cell proteins (HCP) and DNA. Analytical tests for these components are very challenging since (1). they may be present at levels that span a million-fold range, requiring substantial dilutions; (2). are not a single component, often existing as fragments and a variety of structures; (3). require high sensitivity for final steps in process; and (4). are present in very complex matrices including other impurities, the product, buffers, salts and solvents. Due to the complex matrices and the variety of potential analytes, the methods of analysis are not truly quantitative for all species. Although these limitations are well known, the assays are still very much in demand since they are required for approval of new products. Methods for final products, described elsewhere, focus on approaches to achieve regulatory requirements. The study described herein will describe the technical rationale for measuring the clearance of HCP and DNA in the entire bioprocessing to purification from an Escherichia coli-derived expression system. Three analytical assays, namely, reversed-phase high-performance liquid chromatography (RP-HPLC), enzyme-linked immunosorbent assay (ELISA), and Threshold Total DNA Assay, were utilized to quantify the protein product, HCP and DNA, respectively. Product quantification is often required for yield estimation and is useful since DNA and HCP results are best expressed as a ratio to product for calculation of relative purification factors. The recombinant E. coli were grown to express the protein of interest as insoluble inclusion bodies (IB) within the cells. The IB were isolated by repeated homogenization and centrifugation and the inclusion body slurry (IBS) was solubilized with urea. After refolding the product, the solution was loaded on several commonly used ion exchangers (CM, SP, DEAE, and Q). Product was eluted in a salt gradient mode and fractions were collected and analyzed for product, HCP and DNA. The IBS used for this study contained about 15 mg/ml product, 38 mg/ml HCP and 1.1 mg/ml DNA. Thus, the relative amounts of HCP and DNA in the IBS was excessive, and about 10(3) times greater than typical (because the cells and IB were not processed with the normal number of washing steps during isolation). This was of interest since similar samples may be encountered when working with non-inclusion body systems, such as periplasmic expressions, or in cases where the upstream unit operations under-perform in IB cleaning. The study described herein describes the development of three robust methods that provide the essential process data needed. These findings are of general interest to other projects since applications of similar analytical technology may be used as a tool to develop processes, evaluate clearance of impurities, and produce a suitable product.
为证明在纯化过程中残留宿主细胞杂质已减少或消除,通常需要对生物技术过程中的粗样品进行分析。在开发的后期阶段,随着工艺的进一步完善和确定,需要大量测试来确认不存在残留宿主细胞蛋白(HCP)和DNA。对这些成分的分析测试极具挑战性,原因如下:(1)它们的存在水平可能跨越百万倍范围,需要大量稀释;(2)不是单一成分,通常以片段和多种结构形式存在;(3)在工艺的最后步骤需要高灵敏度;(4)存在于非常复杂的基质中,包括其他杂质、产品、缓冲液、盐和溶剂。由于基质复杂且潜在分析物种类繁多,分析方法并非对所有物种都能真正进行定量。尽管这些局限性众所周知,但这些检测方法仍有很大需求,因为它们是新产品获批所必需的。其他地方描述的针对最终产品的方法侧重于实现监管要求的途径。本文所述的研究将描述从大肠杆菌衍生的表达系统到纯化的整个生物加工过程中测量HCP和DNA清除率的技术原理。分别使用三种分析方法,即反相高效液相色谱(RP-HPLC)、酶联免疫吸附测定(ELISA)和阈值总DNA测定法来定量蛋白质产品、HCP和DNA。产品定量通常用于产量估算,并且很有用,因为DNA和HCP结果最好表示为与产品的比率,以计算相对纯化因子。重组大肠杆菌生长以在细胞内表达目标蛋白作为不溶性包涵体(IB)。通过反复匀浆和离心分离IB,并用尿素溶解包涵体浆液(IBS)。产品复性后,将溶液加载到几种常用的离子交换剂(CM、SP、DEAE和Q)上。产品以盐梯度模式洗脱,收集馏分并分析产品、HCP和DNA。用于本研究的IBS含有约15mg/ml产品、38mg/ml HCP和1.1mg/ml DNA。因此,IBS中HCP和DNA的相对含量过高,比典型情况大约高10³倍(因为在分离过程中细胞和IB未经过正常数量的洗涤步骤处理)。这很有意义,因为在处理非包涵体系统(如周质表达)时,或在上游单元操作在IB清洗方面表现不佳的情况下,可能会遇到类似的样品。本文所述的研究描述了三种强大方法的开发,这些方法提供了所需的基本工艺数据。这些发现对其他项目具有普遍意义,因为类似分析技术的应用可作为开发工艺、评估杂质清除率以及生产合适产品的工具。